These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29255066)

  • 21. How I treat CLL patients with ibrutinib.
    Brown JR
    Blood; 2018 Jan; 131(4):379-386. PubMed ID: 29255067
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minimal residual disease analysis in chronic lymphocytic leukemia: a way for achieving more personalized treatments.
    Ghia P; Rawstron A
    Leukemia; 2018 Jun; 32(6):1307-1316. PubMed ID: 29700386
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frontline Therapy of CLL: Evolving Treatment Paradigm.
    Boddy CS; Ma S
    Curr Hematol Malig Rep; 2018 Apr; 13(2):69-77. PubMed ID: 29480432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Venetoclax Data Prompt Rethink of CLL Therapy.
    Cancer Discov; 2018 Mar; 8(3):OF5. PubMed ID: 29382644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
    Siegel DS; Dimopoulos MA; Ludwig H; Facon T; Goldschmidt H; Jakubowiak A; San-Miguel J; Obreja M; Blaedel J; Stewart AK
    J Clin Oncol; 2018 Mar; 36(8):728-734. PubMed ID: 29341834
    [TBL] [Abstract][Full Text] [Related]  

  • 26. No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy.
    Baliakas P; Mattsson M; Hadzidimitriou A; Minga E; Agathangelidis A; Sutton LA; Scarfo L; Davis Z; Yan XJ; Plevova K; Sandberg Y; Vojdeman FJ; Tzenou T; Chu CC; Veronese S; Mansouri L; Smedby KE; Giudicelli V; Nguyen-Khac F; Panagiotidis P; Juliusson G; Anagnostopoulos A; Lefranc MP; Trentin L; Catherwood M; Montillo M; Niemann CU; Langerak AW; Pospisilova S; Stavroyianni N; Chiorazzi N; Oscier D; Jelinek DF; Shanafelt T; Darzentas N; Belessi C; Davi F; Ghia P; Rosenquist R; Stamatopoulos K
    Haematologica; 2018 Apr; 103(4):e158-e161. PubMed ID: 29269523
    [No Abstract]   [Full Text] [Related]  

  • 27. A Challenging Case of Pseudohyperkalemia in Chronic Lymphocytic Leukemia.
    Alhaj Moustafa M; Malkovska V; Elmahdy S; Catlett J
    J Investig Med High Impact Case Rep; 2017; 5(4):2324709617746194. PubMed ID: 29276712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal management of the young patient CLL patient.
    Allan JN; Furman RR
    Best Pract Res Clin Haematol; 2018 Mar; 31(1):73-82. PubMed ID: 29452669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost of Illness of Japanese Patients with Chronic Lymphocytic Leukemia (CLL), and Budget Impact of the Market Introduction of Ibrutinib.
    Mahlich J; Okamoto S; Tsubota A
    Pharmacoecon Open; 2017 Sep; 1(3):195-202. PubMed ID: 29441498
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.
    Tissino E; Benedetti D; Herman SEM; Ten Hacken E; Ahn IE; Chaffee KG; Rossi FM; Dal Bo M; Bulian P; Bomben R; Bayer E; Härzschel A; Gutjahr JC; Postorino M; Santinelli E; Ayed A; Zaja F; Chiarenza A; Pozzato G; Chigaev A; Sklar LA; Burger JA; Ferrajoli A; Shanafelt TD; Wiestner A; Del Poeta G; Hartmann TN; Gattei V; Zucchetto A
    J Exp Med; 2018 Feb; 215(2):681-697. PubMed ID: 29301866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study.
    Cramer P; Fraser G; Santucci-Silva R; Grosicki S; Dilhuydy MS; Janssens A; Loscertales J; Rule S; Goy A; Traina S; Chan EKH; Diels J; Sengupta N; Mahler M; Salman M; Howes A; Chanan-Khan A
    Leuk Lymphoma; 2018 Sep; 59(9):2075-2084. PubMed ID: 29295653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Established and suggested exposures on CLL/SLL etiology: Results from the CLL-MCC-Spain study.
    Benavente Y; Casabonne D; Costas L; Robles C; Alonso E; de la Banda E; Gonzalez-Barca E; Marcos-Gragera R; Llorca J; Tardón A; Monleon JJ; Aymerich M; Campo E; Gimeno-Vázquez E; Castaño-Vinyals G; Aragonés N; Pollán M; Kogevinas M; de Sanjosé S
    Cancer Epidemiol; 2018 Feb; 52():106-111. PubMed ID: 29289901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.
    Stilgenbauer S; Eichhorst B; Schetelig J; Hillmen P; Seymour JF; Coutre S; Jurczak W; Mulligan SP; Schuh A; Assouline S; Wendtner CM; Roberts AW; Davids MS; Bloehdorn J; Munir T; Böttcher S; Zhou L; Salem AH; Desai M; Chyla B; Arzt J; Kim SY; Verdugo M; Gordon G; Hallek M; Wierda WG
    J Clin Oncol; 2018 Jul; 36(19):1973-1980. PubMed ID: 29715056
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cryptococcal infections in two patients receiving ibrutinib therapy for chronic lymphocytic leukemia.
    Stankowicz M; Banaszynski M; Crawford R
    J Oncol Pharm Pract; 2019 Apr; 25(3):710-714. PubMed ID: 29343153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
    Schuurhuis GJ; Heuser M; Freeman S; Béné MC; Buccisano F; Cloos J; Grimwade D; Haferlach T; Hills RK; Hourigan CS; Jorgensen JL; Kern W; Lacombe F; Maurillo L; Preudhomme C; van der Reijden BA; Thiede C; Venditti A; Vyas P; Wood BL; Walter RB; Döhner K; Roboz GJ; Ossenkoppele GJ
    Blood; 2018 Mar; 131(12):1275-1291. PubMed ID: 29330221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elevated absolute NK cell counts in peripheral blood predict good prognosis in chronic lymphocytic leukemia.
    Wang WT; Zhu HY; Wu YJ; Xia Y; Wu JZ; Wu W; Liang JH; Wang L; Fan L; Li JY; Xu W
    J Cancer Res Clin Oncol; 2018 Mar; 144(3):449-457. PubMed ID: 29299750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early progression of disease as a predictor of survival in chronic lymphocytic leukemia.
    Ahn IE; Farber CM; Davids MS; Grinblatt DL; Kay NE; Lamanna N; Mato A; Nabhan C; Kiselev P; Swern AS; Flick ED; Sullivan K; Sharman JP; Flowers CR
    Blood Adv; 2017 Nov; 1(25):2433-2443. PubMed ID: 29296893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Fraser G; Cramer P; Demirkan F; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Pavlovsky MA; Karlsson C; Hallek M; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Chanan-Khan A
    Leukemia; 2019 Apr; 33(4):969-980. PubMed ID: 30315239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
    Tam CS; Anderson MA; Pott C; Agarwal R; Handunnetti S; Hicks RJ; Burbury K; Turner G; Di Iulio J; Bressel M; Westerman D; Lade S; Dreyling M; Dawson SJ; Dawson MA; Seymour JF; Roberts AW
    N Engl J Med; 2018 Mar; 378(13):1211-1223. PubMed ID: 29590547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic lymphocytic leukaemia.
    Hallek M; Shanafelt TD; Eichhorst B
    Lancet; 2018 Apr; 391(10129):1524-1537. PubMed ID: 29477250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.